PLATELET-DERIVED GROWTH-FACTOR EXPRESSION, MYELOFIBROSIS AND CHRONIC MYELOGENOUS LEUKEMIA

被引：30

作者：

KIMURA, A

KATOH, O

HYODO, H

KURAMOTO, A

SATOW, Y

机构：

[1] Department of Environment and Mutation. and Hematology and Oncology, Research Institute for Radiation Biology and Medicine of Hiroshima University, Hiroshima

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 18卷 / 3-4期

关键词：

PLATELET DERIVED GROWTH FACTOR; PDGF; MYELOFIBROSIS CHRONIC MYELOID LEUKEMIA; CML;

D O I：

10.3109/10428199509059613

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML is often associated with myelofibrosis, and fibrosis in the accelerated phase is one of the diagnostic criteria for this accelerated phase. In this review, the mechanism of myelofibrosis associated with CML is discussed with emphasis on the cell origin of the production and release of platelet derived growth factor (PDGF) and its interaction with marrow fibroblasts. In the initial stage of myelofibrosis in chronic phase CML, atypical small megakaryocytes might leak PDGF, possibly PDGF-AB, together with other growth factors. As the clinical phase of the disease progresses to accelerated or blastic phase, a larger quantity of PDGF-AB or PDGF-BB might be secreted from blastic cells with myeloid phenotype. In addition some fibroblasts may be attracted by the PDGF and proliferate, and deposit collagen as well as fibronectin in the bone marrow stroma.

引用

页码：237 / 242

页数：6

共 47 条

[1]

Lichtman M.A., Chronic myelogenous leukemia and related disorders, Hematology, pp. 202-223, (1990)

[2]

Kantarjian H.M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M., Chronic myelogenous leukemia: a concise update, Blood., 82, pp. 691-703, (1993)

[3]

Speck B., Bortin M.M., Champlin R., Goldman J.M., Herzig R.H., McGlave P.B., Messner H.A., Weiner R.S., Rimm A.A., Allogenic bone–marrow transplantation for chronic myelogenous leukaemia, Lancet, i, pp. 665-668, (1984)

[4]

Yoffe G., Chinault A.G., Talpaz M., Blick M., Kantarjian H.M., Taylor K., Spitzer G., Clonal nature of Philadelphia chromosome positive and negative chronic myelogenous leukemia by DNA hybridization analysis, Exp Hematol, 15, pp. 725-729, (1987)

[5]

Bentley S.A., Biology and pathology of bone marrow connective tissue, Myelofibrosis, Pathophysiology arid Clinical Management, pp. 87-96, (1983)

[6]

Gay S., Gay R.E., Prchal J.T., Immunohistochemical studies of bone marrow collagen, Myelofibrosis and the biology of connective tissue, pp. 291-306, (1984)

[7]

Deuel T.F., Polypeptide growth factors: roles in normal and abnormal cell growth, Ann. Rev. Cell Bid, 3, (1987)

[8]

Heldin C.H., Westemark B., Platelet-derived growth factor: mechanism of action and possible in viva function, Cell Regulation, 1, pp. 555-566, (1990)

[9]

Sporn M.I.B., Roberts A.B., Wakefield L.M., Crombrugghe B., Some recent advances in the chemistry and biology of transforming growth factor-beta, J. Cell. Bid, 105, pp. 1039-1045, (1987)

[10]

Oka Y., Orth D.N., Human plasma epidermal growth factor/β-urogastrone is associated with blood platelets, J. Clin. Invest., 72, pp. 249-259, (1983)

← 1 2 3 4 5 →